Australian government adds hepatitis and diabetes drugs to reimbursement scheme

30 July 2018

Greg Hunt, Australian Minister for Health, released a statement on Monday confirming the addition of Novo Nordisk's (NOV: N) Ryzodeg (insulin degludec/insulin aspart) and AbbVie's (NYSE: ABBV) Maviret (glecaprevir/pibrentasvir) to the country's Pharmaceutical Benefits Scheme (PBS).

The PBS is an Australian system through which the state pays the cost of a patient's treatment rather than patients paying themselves. It is a key step on the road to significant adoption in Australia.

"In excess of 170,000 Australians, who face the many challenges and risks of living with the hepatitis C, are expected to benefit from the listing of Maviret on the PBS from August 1," Mr Hunt said in a statement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK